Downregulation of cyclin-dependent kinase 2 activity and cyclin a promoter activity in vascular smooth muscle cells by p27(KIP1), an inhibitor of neointima formation in the rat carotid artery

Journal of Clinical Investigation

Volumn 99, Issue 10, 1997, Pages 2334-2341

  Chen, Donghui ^a   Krasinski, Kevin ^a   Chen, Dongfen ^a   Sylvester, Amy ^a   Chen, Jun ^b   Nisen, Perry D ^b   Andrés, Vicente ^a,c  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^c ST ELIZABETH'S MEDICAL CENTER   (United States)

Author keywords

adenovirus; cell cycle control; p27(KIP1); restenosis; vascular smooth muscle cells

Indexed keywords

CYCLIN A; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; INHIBITOR PROTEIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INJURY; ARTERY INTIMA PROLIFERATION; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY; CELL CYCLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; GENE OVEREXPRESSION; MALE; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROMOTER REGION; RAT; REPRESSOR GENE; RESTENOSIS; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE;

EID: 0030989329     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI119414     Document Type: Article

References (70)

1. Liu, M.W., G.S. Roubin, and S.B. King. 1989. Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia. Circulation. 79:1374-1387.
2. Fuster, V., L. Badimon, J.J. Badimon, and J.H. Chesebro. 1992. The pathogenesis of coronary artery disease and the acute coronary syndromes. N. Engl. J. Med. 236:242-250.
3. Libby, P., D. Schwartz, E. Brogi, H. Tanaka, and S.K. Clinton. 1992. A cascade model for restenosis: a special case of atherosclerosis progression. Circulation. 86 (Suppl.):III47-III52.
4. Ross, R. 1993. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (Lond.). 362:801-809.
5. Hegele, R.A. 1996. The pathogenesis of atherosclerosis. Clin. Chim. Acta. 246:21-38.
6. Kaltenbach, N., G. Kober, D. Scherer, and C. Vallbracht. 1985. Recurrence rate after successful coronary angioplasty. Eur. Heart J. 6:276-281.
7. Mabin, T.A., D.R. Holmes, Jr., H.C. Smith, R.E. Vlietstra, G.S. Reeder, J.F. Bresnahan, A.A. Bove, L.N. Hammes, L.R. Elveback, and T.A. Orszulak. 1985. Follow-up clinical results in patients undergoing percutaneous transluminal coronary angioplasty. Circulation. 71:754-760.
8. Wijns, W., P.W. Serruys, J.H.C. Reiber, P.J. de Feyter, M. van den Brand, M.L. Simons, and P.G. Hugenholtz. 1985. Early detection of restenosis after successful percutaneous transluminal coronary angioplasty by exercise-redistribution thallium scintigraphy. Am. J. Cardiol. 55:357-361.
9. Leimgruber, P.P., G.S. Roubin, J. Hollman, G.A. Cotsonis, B. Meier, J.S. Douglas, S.B. King, and A.R. Gruentzig. 1986. Restenosis after successful coronary angioplasty in patients with single-vessel disease. Circulation. 73:710-717.
10. Nobuyoshi, M., T. Kimura, H. Nosaka, S. Mioka, K. Ueno, H. Yokoi, N. Hamasaki, H. Horiuchi, and H. Ohishi. 1988. Restenosis after successful percutaneous transluminal coronary angioplasty: serial angiographic follow-up of 229 patients. J. Am. Coll. Cardiol. 12:616-623.
11. RITA Trial Participants. 1993. Coronary angioplasty versus coronary artery bypass surgery: the Randomised Intervention Treatment of Angina (RITA) trial. Lancet. 341:573-580.
12. Califf, R.M., D.F. Fortin, D.J. Frid, W.R. Harlan, E.M. Ohman, J.R. Bengtson, C.L. Nelson, J.E. Tcheng, D.B. Mark, and R.S. Stack. 1991. Restenosis after coronary angioplasty: an overview. J. Am. Coll. Cardiol. 17:2B-13B.
13. Popma, J.J., R.M. Califf, and E.J. Topol. 1991. Clinical trials of restenosis after coronary angioplasty. Circulation. 84:1426-1436.
14. Franklin, S.M., and D.P. Faxon. 1993. Pharmacologic prevention of restenosis after coronary angioplasty: review of the randomized clinical trials. Coronary Artery Dis. 4:232-242.
15. Hanke, H., T. Strohschneider, M. Oberhoff, E. Betz, and K.R. Karsch. 1990. Time course of smooth muscle cell proliferation in the intima and media of arteries following experimental angioplasty. Circ. Res. 67:651-659.
16. Clowes, A., M. Reidy, and M. Clowes, 1983. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle cell growth in the absence of endothelium. Lab. Invest. 49:327-333.
17. Geary, R.L., J.K. Williams, D. Golden, D.G. Brown, M.E. Benjamin, and M.R. Adams. 1996. Time course of cellular proliferation, intimai hyperplasia, and remodeling following angioplasty in monkeys with established atherosclerosis. A nonhuman primate model of restenosis. Arterioscler. Thromb. Vasc. Biol. 16:34-43.
18. Ohno, T., D. Gordon, H. San, V.J. Pompili, M.J. Imperiale, G.J. Nabel, and E.G. Nabel. 1994. Gene therapy for vascular smooth muscle cell proliferation after arterial injury. Science (Wash. DC). 265:781-784.
19. Lindner, V., and M. A. Reidy. 1991. Proliferation of smooth muscle cells after vascular injury is inhibited by an antibody against basic fibroblast growth factor. Proc. Natl. Acad. Sci. USA. 88:3739-3743.
20. Abe, J., W. Zhou, J. Taguchi, N. Takuwa, K. Miki, H. Okazaki, K. Kurokawa, M. Kumada, and Y. Takuwa. 1994. Suppression of neointimal smooth muscle cell accumulation in vivo by antisense cdc2 and cdk2 oligonucleotides in rat carotid artery. Biochem. Biophys. Res. Commun. 198:16-24.
21. Bennett, M.R., S. Anglin, J.R. McEwan, R. Jagoe, A.C. Newby. and G.I. Evan. 1994. Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J. Clin. Invest. 93:820-828.
22. Morishita, R., G.H. Gibbons, K.E. Ellison, M. Nakajima, L. Zhang, Y. Kaneda, T. Ogihara, and V.J. Dzau. 1993. Single intraluminal delivery of antisense cdc2 kinase and proliferating-cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia. Proc. Natl. Acad. Sci. USA. 90: 8474-8478.
23. Morishita, R., G.H. Gibbons, K.E. Ellison, M. Nakajima, H. von der Leyen, L. Zhang, Y. Kaneda, T. Ogihara, and V.J. Dzau. 1994. Intimai hyperplasia after vascular injury is inhibited by antisense cdk 2 kinase oligonucleotides. J. Clin. Invest. 93:1458-1464.
24. Morishita, R., G.H. Gibbons, Y. Kaneda, T. Ogihara, and V.J. Dzau. 1994. Pharmacokinetics of antisense oligodeoxyribonucleotides (cyclin B1 and CDC 2 kinase) in the vessel wall in vivo: enhanced therapeutic utility for restenosis by HVJ-liposome delivery. Gene (Amst.). 149:13-19.
25. Nabel, E.G., Z. Yang, S. Liptay, H. San, D. Gordon, CC. Haudenschild, and G.J. Nabel. 1993. Recombinant platelet-derived growth factor B gene expression in porcine arteries induces intimai hyperplasia in vivo. J. Clin. Invest. 91:1822-1829.
26. Nabel, E.G., Z. Yang, G. Plautz, R. Forough, X. Zhan, C.C. Haudenschild, T. Maciag, and G.J. Nabel. 1993. Recombinant fibroblast growth factor-1 promotes intimal hyperplasia and angiogenesis in arteries in vivo. Nature (Lond.). 362:844-846.
27. Shi, Y., A. Fard, A. Galeo, H.G. Hutchinson, P. Vermani, G.R. Dodge, D.J. Hall, F. Shaheen, and A. Zalewski. 1994. Transcatheter delivery of c-myc antisense oligomers reduces neointimal formation in a porcine model of coronary artery balloon injury. Circulation. 90:944-951.
28. Simons, M., E.R. Edelman, J.-L. DeKeyser, R. Langer, and R.D. Rosenberg. 1992. Antisense c-myb oligonucleotides inhibit intimai arterial smooth muscle cell accumulation in vivo. Nature (Lond.). 359:67-70.
29. King, R.W., P.K. Jackson, and M.W. Kirschner. 1994. Mitosis in transition. Cell. 79:563-571.
30. Heichman, K.A., and J.M. Roberts. 1994. Rules to replicate by. Cell. 79: 557-562.
31. Motokura, T., and A. Arnold. 1993. Cyclins and oncogenesis. Biochim. Biophys. Acta. 1155:63-78.
32. Nurse, P. 1994. Ordering S phase and M phase in the cell cycle. Cell. 79: 547-550.
33. Weinberg, R.A. 1995. The retinoblastoma protein and cell cycle control. Cell. 81:323-330.
34. Morgan, D.O. 1995. Principles of CDK regulation. Nature (Lond.). 374: 131-134.
35. Peter, M., and I. Herskowitz. 1994. Joining the complex: cyclin-dependent kinase inhibitory proteins and the cell cycle. Cell. 79:181-184.
36. Harper, J.W., and S.J. Elledge. 1996. Cdk inhibitors in development and cancer. Curr. Opin. Genet. Devel. 6:56-64.
37. Hunter, T., and J. Pines. 1994. Cyclins and cancer: cyclin D and cdk inhibitors come of age. Cell. 79:573-582.
38. Sherr, C.J., and J.M. Roberts. 1995. Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev. 9:1149-1163.
39. Graña, X., and E.P. Reddy. 1995. Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene. 11:211-219.
40. Kip1-deficient mice. Cell. 85:733-744.
41. Kip1. Cell. 85:721-732.
42. Kip1 display increased body size, muitiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell. 85:707-720.
43. Kip1. J. Clin. Invest. 97:1983-1988.
44. Kip1 and cyclin E, alone or in combination, correlate with survival in young breast cancer patients. Nat. Med. 3:222-225.
45. Kip1 protein: prognostic implications in primary breast cancer. Nat. Med. 3:227-230.
46. Loda, M., B. Cukor, S.W. Tam, P. Lavin, M. Fiorentino, G.F. Draetta, J.M. Jessup, and M. Pagano. 1997. Increased proteosome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat. Med. 3:231-234.
47. Pickering, J.G., L. Weir, K. Rosenfield, J. Stetz, J. Jekanowski, and J.M. Isner. 1992. Smooth muscle cell outgrowth from human atherosclerotic plaque: implications for the assessment of lesion biology. J. Am. Coll. Cardiol. 20:1430-1439.
48. Rothman, A., T.J. Kulik, M.B. Taubman, B.C. Berk, C.W.J. Smith, and B. Nadal-Ginard. 1992. Development and characterization of a cloned rat pulmonary arterial smooth muscle cell line that maintains differentiated properties through multiple subcultures. Circulation. 86:1977-1986.
49. Henthorn, P., P. Zervos, M. Raducha, H. Harris, and T. Kadesch. 1988. Expression of a human placental alkaline phosphatase gene in transfected cells: use as a reporter for studies of gene expression. Proc. Natl. Acad. Sci. USA. 85: 6342-6346.
50. Andrés, V., S. Fisher, P. Wearsch, and K. Walsh. 1995. Regulation of Gax homeobox gene transcription by a combination of positive factors including MEF2. Mol. Cell Biol. 15:4272-4281.
51. Pastore, C., L.J. Feldman, M. Perricadet, and P.O. Steg. 1994. Intraluminal delivery of a pluronic gel enhances adenovirus-mediated arterial gene transfer. Circulation. 90(Suppl.):I-517.
52. March, K.L., J.E. Madison, and B.C. Trapnell. 1995. Pharmacokinetics of adenoviral vector-mediated gene delivery to vascular smooth muscle cells: modulation by poloxamer 407 and implications for cardiovascular gene therapy. Human Gene Therapy. 6:41-53.
53. Feldman, L.J., P.O. Steg, L.P. Zheng, D. Chen, M. Kearney, S.E. McGarr, J.J. Barry, J.-F. Dedieu, M. Perricaudet, and J.M. Isner. 1995. Low-efficiency of percutaneous adenovirus-mediated arterial gene transfer in the atherosclerotic rabbit. J. Clin. Invest. 95:2662-2671.
54. Wei, G.L., K. Krasinski, M. Kearney, J.M. Isner, K. Walsh, and V. Andrés. 1997. Temporally and spatially coordinated expression of cell cycle regulatory factors after angioplasty. Circ. Res. 80:418-426.
55. Henglein, B., X. Chenivesse, J. Wang, D. Eick, and C. Bréchot. 1994. Structure and cell cycle-regulated transcription of the human cyclin A gene. Proc. Natl. Acad. Sci. USA. 91:5490-5494.
56. Schulze, A., K. Zerfass, D. Spitkovsky, S. Middendorp, J. Berges, K. Helin, P. Jansen-Dürr, and B. Henglein. 1995. Cell cycle regulation of the cyclin A gene promoter is mediated by a variant E2F site. Proc. Natl. Acad. Sci. USA. 92:11264-11268.
57. Clowes, A. W., and M.M. Clowes. 1985. Kinetics of cellular proliferation after arterial injury. II. Inhibition of smooth muscle growth by heparin. Lab. Invest. 52:611-616.
58. Schulze, A., K. Zerfass-Thome, J. Bergès, S. Middendorp, P. Jansen-Dürr, and B. Henglein. 1996. Anchorage-dependent transcription of the cyclin A gene. Mol. Cell. Biol. 16:4632-4638.
59. Girard, F., U. Strausfeld, A. Fernández, and N. Lamb. 1991. Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell. 67: 1169-1179.
60. Pagano, M., R. Pepperkok, F. Verde, W. Ansorge, and G. Draetta. 1992. Cyclin A is required at two points in the human cell cycle. EMBO (Eur. Mol. Biol. Organ) J. 11:961-971.
61. van den Heuvel, S., and E. Harlow. 1993. Distinct roles for cyclin-dependent kinases in cell cycle control. Science (Wash. DC). 262:2050-2054.
62. Koyama, H., E.W. Raines, K.E. Bornfeldt, J.M. Roberts, and R. Ross. 1996. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of cdk2 inhibitors. Cell. 87:1069-1078.
63. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes Dev. 8:9-22.
64. Reynisdóttir, I., K. Polyak, A. Iavarone, and J. Massagué. 1995. Kip1/Cip and Ink4 cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-β. Genes Dev. 9:1831-1845.
65. Chang, M.W., E. Barr, J. Seltzer, Y. Jiang, G.J. Nabel, E.G. Nabel, M.S. Parmacek, and J.M. Leiden. 1995. Cytostatic gene therapy for vascular proliferative disorders with a constitutively active form of the retinoblastoma gene product. Science (Wash. DC). 267:518-522.
66. Chang, M.W., E. Barr, M.M. Lu, K. Barton, and J.M. Leiden. 1995. Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. J. Clin. Invest. 96: 2260-2268.
67. Yang, Z.-Y., R.D. Simari, N.D. Perkins, H. San, D. Gordon, G.J. Nabel, and E.G. Nabel. 1996. Role of p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. Proc. Natl Acad. Sci. USA. 93:7905-7910.
68. Speir, E., R. Modali, and E.-S. Huang. 1994. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science (Wash. DC). 265:391-394.
69. KIP1 blocks cyclin E-dependent transactivation of cyclin A gene expression. Mol. Cell. Biol. 17:407-415.
70. Dimri, G.P., M. Nakanishi, P.-Y. Desprez, J.R. Smith, and J. Campisi. 1996. Inhibition of E2F activity by the cyclin-dependent protein kinase inhibitor p21 in cells expressing or lacking a functional retinoblastoma protein. Mol. Cell. Biol. 16:2987-2997.